Cytopenia in Influenza and possible treatment strategies (Drug and Vaccine)

Jamshid Ayatollahi¹, Seyed Hossein Shahcheraghi^{*,1}

¹Infectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran *Corresponding author: Seyed Hossein Shahcheraghi, Infectious Diseases Research Center, Shahid Sadoughi Hospital, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Email: <u>shahcheraghih@gmail.com</u>

DOI: 10.22034/HBB.2019.20 Received: October 20, 2019; Accepted: November 10, 2019 ABSTRACT

Viruses consistently present a major health danger and require a proper, balanced reaction from our immune system. Among viruses, human influenza viruses often cause morbidity and mortality, especially in populations at high risk. These viruses cause apoptosis in peripheral blood monocytes and tissue culture cells. Hemophagocytosis-induced pancytopenia has also been frequently correlated with the newly emerging influenza virus infection in latest years. Leukopenia, particularly in influenza B virus, has been discovered to be a common finding in influenza infection. If the virus and the resulting antiviral reaction continue, the inflammatory feedback on the hematopoietic system becomes chronic. Here, we have reviewed effect of Influenza on hematological factors specially cytopenia.

1

Keywords: Influenza virus, hematological factors, cytopenia

INTRODUCTION

Viruses are Small binding intracellular parasites requiring replication of host cellular machines. That said, there is a huge range of viruses, even medically appropriate ones. Viruses that can infect people in the range of 20 to 260 nm are estimated to be at least 30 distinct kinds and can trigger pathologies, ranging frommeningitis, enterocolitis,

manifestations, encephalitis, respiratory sexually transmitted diseases, and hepatitis [1-7]. Viruses are structurally made up of a protein capsid that protects their genomic material and in some instances promotes entry into the host cell. Some viruses with the lipid bilayer enveloped viruses that also contain membrane glycoproteins can communicate with entry receptors on the surface of the host cells can also be encircled [8,9]. The virus genome may consist of DNA

or RNA. RNA genomes can be coded, similar to a mRNA molecule (positive-strand RNA) or have a supplementary RNA molecule (negative-strand) to be copied into a positive strand that can then be translated into a cellular machine [10-15].

Viruses consistently present a major health danger and require a proper, balanced reaction from our immune system. Indeed, both the virus itself and the subsequent immune response can have a tremendous effect on the hematopoietic cycle. This can be useful as it helps increase the body cell response to fix the viral infection. However, if the virus and the resulting antiviral reaction continue, the inflammatory feedback on the hematopoietic system becomes chronic [16-20].

About Human influenza viruses

Viral infections are entered from epithelial or mucosal barriers that cause local invasion. Viral RNA in infected cells is acknowledged during influenza virus infection by pathogen recognition receptors (PRRs), which its result the secretion of pro-inflammatory is cytokines, type I interferons, chemokines, and eicosanoids [20-22]. CD8 + T, plasmacytoidand NK cells are also all involved in cytotoxicity and viral infection control [11-14]. Human influenza viruses cause morbidity often and mortality,

especially in populations at high risk [21,22].

The categories of main influenza (H1N1) is shown in Table 1.

They are single-stranded RNA (ssRNA) and Orthomyxoviridae family members. This family reflects enveloped viruses whose genome consists of segmented single-strand negative-sense RNA sections [24]. This family has four genera: A, B, C and Thogoto viruses, of which only genera A and B are clinically applicable to individuals. The nucleoprotein loosely encapsidates the eight genome sections of influenza A and B viruses [25]. Influenza virus is comparatively susceptible to harmful environmental effects as an enveloped virus. However, it can survive up to several hours depending on environmental conditions (humidity and temperature) and significantly longer in water at low temperatures (< 20 °C). Influenza viruses are susceptible to lipid and detergent. Depending on the type of virus, they are also susceptible to heat and low pH [26,27]. When assessing human infections, the hematological factors are regularly evaluated. Surprisingly, in tiny animal models they are rarely determined. Influenza A Virus (IAV) infection represents a prevalent acute infection in both human and veterinary medicine with a high disease burden. The mouse represents a well-

Cytopenia in Influenza

established model of IAV susceptibility in an adaptive host [25-28].

The effects of Influenza virus on blood cells

Influenza virus has been proved to cause apoptosis in peripheral blood monocytes and tissue culture cells [27]. The immunopathological mechanisms and the role played by leukocyte virus infection in relation to disease pathology in general and leukocyte death in particular have not been clarified [21,22]. Early lymphopenia has

Cytopenia in Influenza

been reported in infected patients and it has been shown that human inoculation with virus causes a reduction in T- and B-cell numbers during disease [23].

Hematological abnormalities such as pancytopenia or isolated leucopenia are also known to be associated with influenza infection that is shown in Table 2.

Types of category	Testing	Reference
А	No for H1N1	
B1	No for H1N1	
B2	No for H1N1	[23]
С	Test for H1N1 is essential with starting treatment	

Table 1. Categorization of influenza H1N1

Table 2. The most types of cytopenia in influenza infection

Type of cytopenia	Reference
Lymphocytopenia	[29-32]
Thrombocytopenia	[33,34]
Eosinopenia	[35]
Leukopenia	[36]

Hemophagocytosis-induced pancytopenia has also been frequently correlated with the newly emerging avian influenza virus infection in latest years. Leukopenia, particularly in influenza B virus, has not been discovered to be a rare finding in influenza infection [37]. Leukopenia is self-limited in most circumstances and usually resolves spontaneously soon after the subsidence of fever [38]. It has been suggested that transient influenza A-induced leukopenia in peripheral blood lymphocytes is caused by Fas-FasL-mediated apoptosis [39].

Lymphocytopenia was a feature of serious influenza and also a significant risk of nosocomial infection in hospitalized patients with serious influenza, long neglected [29,40].

During influenza A infections, leucopenia is known to happen commonly, but thrombocytopenia, pancytopenia, and anemia are uncommon. There are few reports that the fresh virus A (H1N1) could lead to cytopenias. In a Chinese research of 426 instances, lymphopenia was discovered in adolescents at a rate of 68 % while in kids it was discovered almost 92 % [41].

Treatment of cytopenia caused by Influenza virus

Some treatments that may be used include:

Drugs that stimulate the bone marrow are very good. For chemotherapy-induced neutropenia and some other causes, the growth factors Leukine, Neulasta, or Neupogen may be applied to induce the creation of white blood cells [42-45]. For chemotherapy-induced anemia, there are also some medications that may be used [45] 3). Also. blood transfusions. (Table immunosuppressive drugs if influenza is due to an autoimmune condition and finally, bone marrow transplant or stem cell transplant in influenza related to cancer [45,46].

Type of cytopenia	Treatment	Reference
Lymphocytopenia	Epoetin alpha	[42, 43]
Thrombocytopenia	Prednisone, Dexamethasone, Promacta	[45, 47]
Eosinopenia	Darbepoetin alfa, Epoetin alpha	[45-47]
Leukopenia	Darbepoetin alfa	[45-47]
Chemotherapy-induced anemia	Epoetin alpha	[45]
Chemotherapy-induced neutropenia	Leukine, Neulasta, Neupogen	[42-45]

 Table 3. Drugs list for the types of cytopenia

DISCUSSION

Leucopenia, anemia and thrombocytopenia observed during influenza A (H1N1) infection are reported to have improved with the resolution of symptoms of viral infection and not to cause permanent cytopenia and serious complications [36].

A study investigated the prevalence of cytopenia, which in children positive for influenza A (H1N1) infection is a hematological complication. In the three primary cell groups, platelets, leucocytes and erythrocytes, cytopenia was determined with declines. Decreases were also ana-lyzed in leucocyte and leucocyte [43]. A platelet count below 150,000/mm³ has been assessed in all age groups as thrombocytopenia.A leucocyte count below 6,000/mm³ in kids under 2 years of age and a leucocyte count below 4,000/mm³ in kids between 2-17 years of regarded leucopenia. was А age lymphocyte count below 1,800/mm³ in kids under 2 years of age and a lymphocyte count below 1,000/mm³ in kids between 2-17 years of age was regarded lymphopenia; Neutrophil counts below 1,100/mm³ in kids under 2 years of age and neutrophil counts below 1,500/mm³ in kids between 2-17 years of age were regarded to be neutropenia. Hemoglobin values below 10.5 g/dL in children 2 years of age, below

subgroups (lymphocytes, granulocytes)

11.5 g/dL in children 2-9 years of age, below 12.5 g/dL in boys 10-17 years of age and below 12.9 g/dL in girls 10-17 years of age were recognized as anemia[44]. Hematocrites below 32 percent, 33 percent, 35 percent and 36 percent, respectively, were regarded anemia after the iron deficiency and vitamin B12 deficiency excluded. anemias were Α cytopeniagiemsa stain was performed for each patient (classical method) and peripheral blood smears. A hematology specialist then evaluated the results. Leukopenia in patients with atypical lymphocytes (Larger cytoplasm of rare eosinophilic granules and normal lymphocytes 1.5-2 times larger than expected) was observed. The report on peripheral smear indicated that lymphocytes being were served. Furthermore, the blood count results of leukopenia were consistent with peripheral smear outcomes of leukopenia. Atypical blastic species-specific cells have not been observed [45].

Influenza infection increases the incidence of acute MI [45,46] within 7 days of detection of type A or type B viruses, whereas after day 7 there is no increased incidence. There is no understanding of the exact mechanism by which influenza contributes to acute coronary syndrome and

Cytopenia in Influenza

cardiovascular disease. In humans, platelets are central to the thrombosis process and uncontrolled platelet activation is the main factor in unstable coronary syndromes and acute MI. In addition to their role in thrombosis, platelets in various types of infections contribute significantly to the immune response. Platelets involve and heterotypic form aggregates with neutrophils during the initial stages of infection [46]. In Gram-positive bacterial infections, heterotypic aggregates between platelets and neutrophils are observed, with Gram-negative bacterial components and single-stranded virus infections such as encephalomyocarditis virus. Platelets have a critical adaptive immune function by forming platelet-bacterial complexes that slow bacterial clearance and increase immunity to antibacterial agents. Influenza virus is acknowledged as a virus receptor by cell-surface sialic acid. Influenza creates efficient infection in the epithelial cells of the lungs, which can lead to different levels of disease severity. In humans, Toll-like receptor 7 (TLR7) is one pattern recognition receptor which mediates the original reaction to ssRNA viral nucleic acids [47]. Once activated, TLR7 causes a cascade of signaling events leading to main interferon secretion and immune system activation. Platelets express TLR7 at any

specified moment, although not all platelets in a single express TLR7. Whether platelets contribute to the general activation of neutrophils through other TLRs (TLR7 which becomes activated by viral ligand) is unknown during influenza infection or if the connection between platelets and neutrophils during infection becomes pathologically imbalanced [48,49].

Although there have been many reports of influenza A H1N1 illness, including prevention, pathogenic mechanism, new drug research, virus identification and growth of vaccines, very few scientists have concentrated on the hematological markers of this worldwide pandemic disease. Therefore, it is essential to establish convenient hematologic diagnostic criteria as a reference [50,51].

CONCLUSION

Initial diagnosis, treatment, and control of influenza are of excessive worth for the future. In this study, we reviewed effect of Influenza on cytopenia. We know that if the virus and the resulting antiviral reaction continue, the inflammatory feedback on the hematopoietic system becomes chronic. Therefore, it is essential to establish convenient hematologic diagnostic criteria as a reference.

Cytopenia in Influenza REFERENCES

[1]. Husain M. Avian influenza A (H7N9) virus infection in humans: epidemiology, evolution, and pathogenesis. *Infect Genet Evol*, 2014; 28: 304-12.

[2]. Kaminski DA, Lee FE-H, Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design. *Front Immunol*, 2011; 2.

[**3**]. Strohmeier S, Amanat F, Krammer F, Cross-Reactive antibodies binding to the Influenza virus subtype H11 Hemagglutinin. *Pathogens*, 2019; 8(4): 199.

[4]. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D, Viral and bacterial interactions in the upper respiratory tract. *PLoS Pathog*, 2013; 9(1): 1003057.

[5]. Zolotarova O, Budzanivska I, Leibenko L, Radchenko L, Mironenko A. Antigenic site variation in the Hemagglutinin of pandemic Influenza A (H1N1) pdm09 viruses between 2009–2017 in Ukraine. *Pathogens*, 2019; 8(4): 194.

[6]. Park JE, Son WS, Ryu Y, Choi SB, Kwon O, Ahn I, Effects of temperature, humidity, and diurnal temperature range on influenza incidence in a temperate region. *Influenza Other Respi Viruses*, 2019.

[7]. de Vries E, Du W, Guo H, de Haan CA, Influenza A Virus Hemagglutinin– Neuraminidase–Receptor Balance:

Preserving virus motility. *Trends Microbiol*, 2019.

[8]. Lafond K, Praptiningsih C, Mangiri A, Syarif M, Triada R, Mulyadi E, Septiawati C, Setiawaty V, Samaan G, Storms A. Seasonal Influenza and Avian Influenza A (H5N1) virus surveillance among inpatients and outpatients, East Jakarta, Indonesia, 2011-2014. *Emerg Infect Dis*, 2019; 25(11): 2031.

[9]. Korneev D, Kurskaya O, Sharshov K, Eastwood J, Strakhovskaya M. Ultrastructural aspects of photodynamic inactivation of highly pathogenic Avian H5N8 Influenza virus. *Viruses*, 2019; 11(10): 955.

[10]. Peng X, Luo G, Wu Z, Wen W, Zhang X, Wang SF. Fluorescent magnetic catalytic nanospheres for dual-modality detection of H9N2 Avian Influenza virus. *ACS Applied Materials & Interfaces*, 2019.
[11]. Wolff GG, Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017–2018 influenza season. *Vaccine*, 2019.

[12]. Moriyama M, Koshiba T, Ichinohe T, Influenza A virus M2 protein triggers mitochondrial DNA-mediated antiviral immune responses. *Nat Commun*, 2019; 10(1): 1-14.

Cytopenia in Influenza

[13]. Yu L, Wang Z, Chen Y, Ding W, Jia H, Chan JF-W, To KK-W, Chen H, Yang Y, Liang W. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A (H7N9) virus. *Clin Infect Dis*, 2013; 57(10): 1449-57.

[14]. Zheng S, Tang L, Gao H, Wang Y, Yu F, Cui D, Xie G, Yang X, Zhang W, Ye X, Benefit of early initiation of neuraminidase inhibitor treatment to hospitalized patients with avian influenza A (H7N9) virus. *Clin Infect Dis*, 2017; 66(7): 1054-60.

[**15**]. Liu Z, Huang Y, Cao B-B, Qiu Y-H, Peng Y-P, Th17 cells induce dopaminergic neuronal death via LFA-1/ICAM-1 interaction in a mouse model of Parkinson's disease. *Mol Neurobiol*, 2017; 54(10): 7762-76.

[16]. Pascutti MF, Erkelens MN, Nolte MA, Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output. *Front Immunol*, 2016; 7: 364.

[17]. Brincks EL, Katewa A, Kucaba TA, Griffith TS, Legge KL, CD8 T cells utilize TRAIL to control influenza virus infection. *J Immunol*, 2008; 181(7): 4918-25.

[18]. Swiecki M, Gilfillan S, Vermi W, Wang Y, Colonna M, Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and

CD8+ T cell accrual. *Immunity*, 2010; 33(6): 955-66.

[**19**]. Robbins SH, Bessou G, Cornillon A, Zucchini N, Rupp B, Ruzsics Z, Sacher T, Tomasello E, Vivier E, Koszinowski UH, Natural killer cells promote early CD8 T cell responses against cytomegalovirus. *PLoS Pathog*, 2007; 3(8): 123.

[20]. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC, Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. *J InfectDis*, 2009; 199(10): 1435-41.

[21]. Briese T, Chowdhary R, Da Rosa AT, Hutchison SK, Popov V, Street C, Tesh RB, Lipkin WI, Upolu virus and Aransas Bay virus, two presumptive bunyaviruses, are novel members of the family Orthomyxoviridae. *J Virol*, 2014; 88(10): 5298-5309.

[22]. Blümel J, Burger R, Drosten C, Gröner A, Gürtler L, Heiden M, Hildebrandt PDM, Jansen B, Klamm H, Montag-Lessing T, Influenza virus. *Transfus Med Hemother*, 2008; 35(1): 42.

[23]. Chudasama RK, Verma PB, Amin CD, Gohel B, Savariya D, Ninama R, Correlates of severe disease in patients admitted with 2009 pandemic influenza A (H1N1) infection in Saurashtra region, India. *Indian J Crit Care Med*, 2010; 14(3): 113.

[24]. Schlenke P, Sibrowski W, Inhalt Band36, 2009. *Transfus Med Hemother*, 2009;36(6).

[25]. Preusse M, Schughart K, Wilk E, Klawonn F, Pessler F, Hematological parameters in the early phase of influenza A virus infection in differentially susceptible inbred mouse strains. *BMC Res Notes*, 2015; 8(1): 225.

[26]. Wang GF, Li W, Li K, Acute encephalopathy and encephalitis caused by influenza virus infection. *Curr Opin Neurol*, 2010; 23(3): 305-11.

[27]. La Gruta NL, Kedzierska K, Stambas J, Doherty PC, A question of self-preservation: immunopathology in influenza virus infection. *Immunol Cell Biol*, 2007; 85(2): 85-92.

[**28**]. Nichols JE, Niles JA, Roberts NJ, Human lymphocyte apoptosis after exposure to influenza A virus. *J Virol*, 2001; 75(13): 5921-29.

[29]. Nichols WG, Guthrie KA, Corey L, Boeckh M, Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. *Clin Infect Dis*, 2004; 39(9): 1300-1306.

[**30**]. Cunha BA, Pherez FM, Schoch P, Diagnostic importance of relative lymphopenia as a marker of swine influenza (H1N1) in adults. *Clin Infect Dis*, 2009; 49(9): 1454-56.

[**31**]. Chiappini E, Galli L, Azzi A, Resti M, Bonsignori F, De Martino M, Lymphocytopenia as a marker for pandemic influenza A/H1N1 2009 virus infection in children. *J Med Virol*, 2011; 83(1): 1-4.

[**32**]. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC, Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. *J Infect Dis*, 2009; 199 (10): 1435-41.

[**33**]. Koupenova M, Corkrey HA, Vitseva O, Manni G, Pang CJ, Clancy L, Yao C, Rade J, Levy D, Wang JP, The role of platelets in mediating a response to human influenza infection. *Nat Commun*, 2019; 10(1): 1780.

[**34**]. Hamiel U, Kventsel I, Youngster I, Recurrent immune thrombocytopenia after influenza vaccination: a case report. *Pediatrics*, 2016; 138(6): 124.

[**35**]. Xu T, Qiao J, Zhao L, Wang G, He G, Li K, Tian Y, Gao M, Wang J, Wang H, Acute respiratory distress syndrome induced by avian influenza A (H5N1) virus in mice. *Am J Respir Crit Care Med*, 2006; 174(9): 1011-17.

Cytopenia in Influenza

[**36**]. Shen C-F, Huang S-C, Wang S-M, Wang J-R, Liu C-C. Decreased leukocytes and other characteristics of laboratory findings of influenza virus infections in children. *J Microbiol Immunol Infect*, 2008; 41(4): 294-300.

[**37**]. Smith JN, Kanwar VS, MacNamara KC, Hematopoietic stem cell regulation by type I and II interferons in the pathogenesis of acquired aplastic anemia. *Front Immunol*, 2016; 7: 330.

[**38**]. Antoniadou A, Giamarellou H, Fever of unknown origin in febrile leukopenia. *Infect Dis Clin North Am*, 2007; 21(4): 1055-90.

[**39**]. Zhou F, Li H, Gu L, Liu M, Xue C-x, Cao B, Wang C, Risk factors for nosocomial infection among hospitalised severe influenza A (H1N1) pdm09 patients. *Respir Med*, 2018; 134: 86-91.

[**40**]. Cao B, Li X-W, Mao Y, Wang J, Lu H-Z, Chen Y-S, Liang Z-A, Liang L, Zhang S-J, Zhang B, Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. *N Engl J Med*, 2009; 361(26): 2507-17.

[41]. Kwon MK, Kim MR, Park EY, Lee KH, Yoon HS, Kim KN, Lee KM, Clinical analysis of acute respiratory tract infections

by influenza virus in children. J Korean Pediatr Soc, 2002; 45(12): 1519-27.

[42]. Shizuma T. Immune thrombocytopenia following influenza virus infection and influenza vaccine administration. Virol Mycol, 2014; 2: 2161. [43]. Yazgan H, Yokuş O, Çaşkurlu H, Akkaş T, Demirdöven M, Ruhi Toraman A, Cakmak M, Gürel A. Prevalence of cytopenia and evaluation of its clinical significance in children with influenza A (H1N1). Eur J Gen Med, 2010; 7(4):414-18.

[44]. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Acute myocardial infarction after laboratory-confirmed influenza infection. *N Engl J Med*, 2018; 378(4): 345-53.

[**45**]. Koupenova M, Vitseva O, MacKay CR, Beaulieu LM, Benjamin EJ, Mick E, Kurt-Jones EA, Ravid K, Freedman JE. Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis. *Blood*, 2014; 124(5): 791-802.

[46]. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S, Speciesspecific recognition of single-stranded RNA via toll-like receptor 7 and 8. *Science*, 2004; 303(5663): 1526-29.

[47]. Koupenova M, Corkrey HA, Vitseva O, Manni G, Pang CJ, Clancy L, Yao C, Rade J, Levy D, Wang JP, The role of platelets in mediating a response to human influenza infection. *Nat Commun*, 2019; 10(1): 1780.

[**48**]. Prince LR, Whyte MK, Sabroe I, Parker LC, The role of TLRs in neutrophil activation. *Curr Opin Pharmacol*, 2011; 11(4): 397-403.

[**49**]. Wang N, Liu X, Zhang Y, Xie Y, Zhao W, Hematologic markers of influenza A H1N1 for early laboratory diagnosis and treatment assessment. *Lab Med*, 2011; 42(10): 607-11.

[50]. Lobo SM, Watanabe ASA, Salomão MLM, Queiroz F, Gandolfi JV, de Oliveira NE,Covello LHS, Sacillotto GH, de Godoy LG, Simões ES, Frini ICM, Da Silva Teixeira RER, Furlan NP, Dutra KR, Nogueira ML, Excess mortality is associated withinfluenza A (H1N1) in patients with severe acute respiratory illness. *J Clin Virol*, 2019; 116: 62-68.

11

Cytopenia in Influenza